Lilly and CoLucid Pharmaceuticals Announce Agreement for Lilly To Acquire CoLucid
18 janv. 2017 06h45 HE
|
CoLucid Pharmaceuticals, Inc
$960 million deal will enhance Lilly’s existing pain management portfolio for migraine; adds potential near-term launch to its late-stage pipeline INDIANAPOLIS and CAMBRIDGE, Mass., Jan. 18, 2017 ...
CoLucid Pharmaceuticals to Present at the 28th Annual Piper Jaffray Healthcare Conference
28 nov. 2016 13h58 HE
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., Nov. 28, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of...
CoLucid Pharmaceuticals Provides SPARTAN Enrollment Update
14 nov. 2016 08h00 HE
|
CoLucid Pharmaceuticals, Inc
Comparison of 50 mg, 100 mg and 200 mg of lasmiditan oral tablets to placebo for the acute treatment of migraineOver 50% of the expected 2,968 migraine patients enrolled77% of patients enrolled to...
CoLucid Pharmaceuticals Announces 2016 Third Quarter Results and Corporate Highlights
09 nov. 2016 08h00 HE
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., Nov. 09, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) today reported financial and operating results for the quarter ended September 30, 2016. ...
CoLucid Pharmaceuticals to Present at the Stifel 2016 Healthcare Conference
08 nov. 2016 08h00 HE
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., Nov. 08, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of...
CoLucid Pharmaceuticals Announces Additional Analyses of Lasmiditan’s Onset of Action Data from SAMURAI and Supporting Non-Clinical Data
05 oct. 2016 10h54 HE
|
CoLucid Pharmaceuticals, Inc
Lasmiditan (100 mg and 200 mg) oral tablets had onset of action and provided significant headache pain relief as soon as 30 minutes after dosing (p ≤ 0.004) and freedom from the most bothersome...
CoLucid Pharmaceuticals to Present at the Ladenburg Thalmann 2016 Healthcare Conference
26 sept. 2016 07h00 HE
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., Sept. 26, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of...
CORRECTING and REPLACING – CoLucid Pharmaceuticals Provides Interim Update on GLADIATOR
19 sept. 2016 10h43 HE
|
CoLucid Pharmaceuticals, Inc
1,155 patients have been randomized in GLADIATOR, with a retention rate of 74% of those patients 100 mg and 200 mg doses of lasmiditan collectively have been administered over 7,500 times in GLADIATOR...
CoLucid Pharmaceuticals Provides Interim Update on GLADIATOR
19 sept. 2016 07h00 HE
|
CoLucid Pharmaceuticals, Inc
1,155 patients have been randomized in GLADIATOR, with a retention rate of 74% of those patients 100 mg and 200 mg doses of lasmiditan collectively have been administered over 7,500 times in GLADIATOR...
CoLucid Pharmaceuticals Announces Achievement of Secondary Endpoints in SAMURAI
17 sept. 2016 05h30 HE
|
CoLucid Pharmaceuticals, Inc
100 mg and 200 mg doses of lasmiditan were more efficacious than placebo on headache pain relief at the two-hour time point (p < 0.001)100 mg and 200 mg doses of lasmiditan were more efficacious...